![[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommandé
Contenu connexe
Tendances
Tendances (20)
Similaire à Acute Coronary Syndromes
Similaire à Acute Coronary Syndromes (20)
Plus de salaheldin abusin
Plus de salaheldin abusin (20)
Dernier
Dernier (20)
Acute Coronary Syndromes
- 1. Seema Nour MBBCh Interventional Cardiologist Peninsula Regional Hospital
- 13. High Risk Intermediate Risk Low Risk History Known CAD Prior MI Patient presenting with typical symptoms Chest/left arm pain Age >70yrs Diabetes Male Recent cocaine use Physical Exam Pulmonary Edema Hypotension, MR Arrythmias Manifestation of extra-cardiac vascular disease Pain reproducible on exam ECG New transient ST segment depression >1mm T wave inversions in multiple leads New T-wave changes Pathological Q waves St depression 0.5-1mm Normal or unchanged Cardiac Markers Elevated cardiac enzymes Slightly elevated Normal
- 23. TIMI IIIB (94) Conservative Strategy Favored N=920 Invasive Strategy Favored N=7,018 VANQWISH (98) MATE FRISC II (99) TACTICS- TIMI 18 (01) VINO RITA-3 (02) TRUCS ISAR- COOL ICTUS (05) No difference N=2,874 Weight of the evidence
- 45. NEJM 2001
- 47. NEJM 2007
- 59. Most benefit in the first 3 hours whether with lysis or PCI, and after 3 hrs with PCI
- 65. Careful assessment of risk benefit
Notes de l'éditeur
- changes greater than 0.5 mm Bundle-branch block, new T-wave changes Pathological Q waves or resting ST-depression less than 1 mm in multiple lead groups Normal or unchanged ECG
- Score of more than 3 is high risk
- Initial troponin is negative
- Intravenous NTG may be initiated at a rate of 10 mcg per min and increased by 10 mcg per min every 3 to 5 min until relief of symptoms or blood pressure response is noted. A ceiling dose of 200 mcg per min is commonly used. Systolic blood pressure generally should not be reduced to less than 110 mm Hg in previously normotensive patients or to more than 25% below the starting mean arterial blood pressure if hypertension was present
- Why have we moved towards considering these two strategies. Early study Vanquish showed harm with an early invasive strategy, Then came other trials which showed benefit. So in 2002 guidelines, all NST ACS patients should be treated with an invasive approach. Then came Most recently came ICTUS which showed no difference, so guidelines in 2007 were changed to say consider either strategy based on the risk of the patient. NOTE THAT ALL THE TRIALS THAT HAVE FAVORED AN INVASIVE APPROACH SHOW AN IMPROVEMENT IN REDUCTION IN ISCHEMIA. REDUCTION IN DEATH IS INCONSISTENT IN BETWEEN THE TRIALS, however some meta analaysis show some improvement in mortality
- If patient has these low risk features they can be managed medically
- If elected from start to take the early invasive approach
- More bleeding in prasugrel arm but overall benefit outweigh the risk